

## PRESS RELEASE

Basel, Switzerland, September 5<sup>th</sup>, 2019.

**Clinerion and OncologyInformationService partner on delivering real-world data services in oncology by using both partners' technologies to aggregate cancer treatment data from each partner's networks of institutions.**



- The partnership between Clinerion and OncologyInformationService will create a platform of live, aggregated, anonymous, longitudinal cancer patient data from both partner's networks of treatment institutions.
- The resulting real-world database will provide services in oncology to researchers, treating institutions, medical associations and the pharmaceutical industry.

The partnership between Clinerion and OncologyInformationService (O.I.s) will create a platform for oncology which integrates O.I.s's real-world databases with Clinerion's patient data network, via Clinerion's patented patient data analytics technologies. The partners aim to establish a real-world evidence (RWE) database from a network of cancer treating institutions which will also allow real-time query of the participating institutions' electronic medical records (EMRs). This platform will leverage the aggregated data to deliver:

- epidemiological, clinical and health care research analyses, real world data comparison of treatment algorithms, health economic analyses, identification of target patient groups as requested from pharmaceutical companies for value dossiers and HTAs,
- an estimation of eligible patients for clinical trial design, identification of sites treating targeted patients, and identification of eligible patients for CROs,
- real world data analyses for quality of care assessment and epidemiological analysis for medical associations and working groups,
- quality measurement in cancer care referring to clinical outcomes for treating institutions, and
- integration of genomic data to complete the clinical data collected in the network.

O.I.s) provides a deep knowledge of treatment algorithms in oncology and hematology and approved methodologies for collection and analyses of treatment algorithms based on longitudinal real-world data from patient files in treating institutions. O.I.s) will provide the Clinerion partnership with access to its established RWE cooperative group consisting of patient organizations and a network of oncologists/hematologists, its real-world databases and its approved methodologies for collecting and analyzing RWE data.


Clinerion's Patient Network Explorer (PNEx) allows query of anonymized patient data among its network of partner hospitals to generate real-world data based on EMR. In the partnership, Clinerion will provide PNEx technology as the platform to query both partners' databases, taking advantage of its fast data collection and real-time update capability.

The partners' new platform will also incorporate genomic technology and PRO/PRE reporting via an additional partnership with Andaman7.

"The partnership with Clinerion will allow O.I.s) to provide unbiased and complete RWE faster than before and to involve cancer-treating institutions, globally. Data collection with the PNEx technology avoids a work-overload for the physicians or HCPs. O.I.s) will use the resulting enormous, combined database for high-end analyses, meeting the information needs from all stakeholders in the fight against cancer," says Lenka Kellermann, founder and owner of O.I.s).

"This partnership represents a deepening of Clinerion's commitment to providing our real-world data solutions in the oncology space, which represents 40% of all drug development pipeline expenditure," says Ian Rentsch, CEO of Clinerion. "Clinerion's services are otherwise agnostic to treatment area, being based on hospital EMR data."

For the full overview of the Clinerion/O.I.s) ecosystem of partners and processes, please see the attached graphic:



Clinerion and OncologyInformationService will launch their partnership at a special event at the annual conference of the German Society for Haematology and Medical Oncology (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, DGHO), on October 11<sup>th</sup>-14<sup>th</sup>, in Berlin,

Germany. Please contact the press officers below if you would like to attend.

### **About Clinerion**

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion's proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: [www.clinerion.com](http://www.clinerion.com)

Clinerion's Patient Network Explorer:

[www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer](http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer)

For more information, please contact:

Le Vin Chin  
Director, Head of Marketing & Communications  
Clinerion Ltd  
Elisabethenanlage 11, 4051 Basel, Switzerland  
Tel.: +41 61 865 60 54  
[media@clinerion.com](mailto:media@clinerion.com)

### **About OncologyInformationService**

O.I.s) is a leading company providing longitudinal real-world data in solid tumors and hematological malignancies in EUCAN region based on representative samples of institutions and achieving ~10% of treated prevalence. O.I.s) has established a long-term cooperation with the majority of pharmaceutical companies offering anticancer medications.

OncologyInformationService website: [www.oncologyinformationservice.com](http://www.oncologyinformationservice.com)

For more information, please contact:

Zhenya Kharitonova  
Project Manager Patient Advocacy, Marketing & Communication  
OncologyInformationService  
Kaiser-Joseph-Str. 271, 79098 Freiburg, Germany  
Tel.: +49-761-383994-24  
[kharitonova@oncologyinformationservice.com](mailto:kharitonova@oncologyinformationservice.com)